SOPHiA GENETICS' First Companion Diagnostics Deals Mark a Strategic Inflection Point
New CEO Ross Muken's debut call lands two AstraZeneca CDx programs, an MSK joint venture, and 27% revenue growth — evidence the company is executing on its pivot toward regulated precision medicine.
SOPH · Earnings Call · 2026-08-04
A New CEO and a Clearer Destination
Ross Muken opened his first earnings call as CEO with a definitive statement of intent: “Today is my first earnings call as CEO... we intend to become the AI platform for precision medicine, the connected intelligence layer that makes every clinical decision smarter than the one before it.” — 2026-08-04 That vision is not new — the company has talked about AI platform ambitions for years — but the evidence of execution is now far more concrete. Q2 revenue grew 27% year-over-year to $23.3 million, with analysis volumes up 22% to a record 115,000. More tellingly, adjusted EBITDA loss improved 27% year-over-year, dropping 60% of incremental revenue to the bottom line. The U.S. market was the standout: revenue +64% on volume +60%, driven by hospitals and labs increasingly bringing testing in-house.The acceleration in the U.S. is built on a structural shift the company has been touting for several quarters. As reimbursement rates firm and sequencing costs fall, central labs and large health systems are seeing the economic logic of in-house testing. George Cardoza, CFO, put it simply: “We are seeing a real inflection in the U.S. market... The growth has been especially impressive given the increasingly large base in the U.S.” — 2026-08-04 The company's net dollar retention hit 117% (up 1,000 basis points year-over-year) and annualized churn remained below 1%, underscoring the stickiness of the platform once customers adopt it.
Two Firsts: CDx and a Joint Venture
The most consequential news is the announcement of two companion diagnostic programs with AstraZeneca — the first CDx wins in SOPHiA's history. These are not incremental; they represent a fundamental move up the value chain from a laboratory services/software provider to a regulated diagnostic partner.Management emphasized that these are multiyear agreements with tiered milestones, with meaningful revenue contribution expected in 2027 and beyond. The strategic logic extends beyond the immediate contract: by embedding themselves in regulatory pathways, SOPHiA can collect richer data and build real-world evidence assets — a direct line to the real world evidence story the company has been developing.We will develop our solid tumor application into a decentralized companion diagnostic... the second CDx program will leverage our hematological oncology application to support a therapy for patients with blood cancer.
Equally telling is the memorandum of understanding with Memorial Sloan Kettering to form a joint venture. The partnership aims to build an “AI lab of the future” in New York City, combining MSK's clinical and data assets with SOPHiA's platform to develop new applications and clinical intelligence tools. This is a validation of the company's clinical intelligence thesis — and a potential blueprint for how the platform can expand beyond genomics into multimodal data.
Financial Strength and a Raised Bar
The company ended Q2 with $107.7 million in cash after an oversubscribed public offering that raised ~$57.5 million. That liquidity gives management confidence to invest in the U.S. commercial team and pharma partnerships. Full-year revenue guidance was raised to $94–96 million (22–24% growth), with adjusted EBITDA loss guidance reaffirmed at $29–32 million. The company reiterated its path to profitability, approaching EBITDA breakeven by year-end and turning positive in H2 2027.The prior quarter's call had already hinted at the potential of pharma partnerships. In Q1 2026, then-President Ross Muken said: “We're much more confident that the type of business we're bringing online is recurring, can be repeated and can be scaled.” — Ross Muken, Company President · 2026-05-05 That confidence now has concrete proof points. The company also continues to expand its customer base — 24 new customers in the quarter, bringing the total to 542 core genomic customers. The pipeline remains strong, with both clinical and biopharma pipelines exceeding $100 million each.
What stands out is how much of this is company-unique. The CDx program wins and the MSK JV are not theme-driven; they are deliberate strategic moves to own the regulated diagnostic layer. While some of the company's peers report similar tailwinds from AI adoption or reimbursement changes, no other small-cap we track has announced a first-ever CDx relationship with a top-tier pharma on this call. This is a genuine inflection point, and the market's reaction (the stock trades at a ~$350M market cap) suggests investors are still waiting for the proof. With the foundation laid, the next two quarters will be critical to demonstrate that the new growth trajectory is sustainable.